IL

Ingrid Lundberg

Clinical Advisor at Kezar Life Sciences

Dr. Ingrid Lundberg is professor in rheumatology at Karolinska Institutet combined with a position as senior consultant at Karolinska University hospital. She completed her MD and PhD at Karolinska Institutet as well.

Dr. Lundberg established a myositis clinic with a dedicated multidisciplinary team in 1993 at Karolinska University Hospital. This clinic has formed the basis of a translational research project with the aim to achieve improved understanding of molecular mechanisms that lead to muscle weakness and immune reactivity in patients with myositis.

Through her research her team has demonstrated that physical exercise, in contrast to the recommendations at that time, leads to increased muscle strength and improved performance. Dr Lundberg and her team have detected a new myositis specific autoantibody, anti-FHL1 autoantibodies that are associated with a severe phenotype of myositis, and they have identified antigen specific T cells targeting histidyl-tRNA synthetase.

Dr Lundberg and her team have undertaken therapeutic mechanistic studies using anti-TNF, and anti-IL-1 treatment, high dose IVIg and abatacept as well as physical exercise with studies on clinical outcome and effect on molecular expression in muscles and peripheral blood.

Dr Lundberg is member of a team that founded and developed an international, multidisciplinary, web-based myositis register, www.euromyositis.eu which now has more than 5 000 patients from 23 centers world-wide enrolled. She is the PI of the International Myositis Classification Criteria Project (IMCCP) published in 2017 “European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups” (Lundberg,IE et al. Ann Rheum Dis. 76:1955-1964 2017; Arthritis Rheumatol.69:2271-2282, 2017.)